Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies, called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone. The company was founded in 2003 and is based in Driebergen, the Netherlands.
Funding Rounds (2) - $70.2MUpdate
Pfizer Venture Investments (PVI) serves as the venture capital arm of Pfizer, supporting a...
LSP (Life Sciences Partners) is a leading independent European investment firm, providing...
Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing...
Venture capital subsidiary
Padualaan 8 (postvak 133)
Utrecht, 3584 CH